secwatch / observer
8-K filed November 1, 2023, 7:59 PM ET ticker SPRO CIK 0001701108
leadership confidence high sentiment neutral materiality 0.55

Spero Therapeutics appoints Esther Rajavelu as CFO and CBO effective Nov 6

Spero Therapeutics, Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Esther Rajavelu

Chief Financial Officer and Chief Business Officer
SPRO · Spero Therapeutics, Inc.
Effective
2023-11-06
Filed
November 1, 2023, 7:59 PM ET
On October 30, 2023, the Board of Directors (the “Board”) of Spero Therapeutics, Inc. (the “Company”) appointed Esther Rajavelu as the Company’s Chief Financial Officer and Chief Business Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Esther Rajavelu was appointed as Chief Financial Officer and Chief Business Officer at Spero Therapeutics, Inc..

Action
appointed
Role
Chief Financial Officer and Chief Business Officer
Exact text from the filing
On October 30, 2023, the Board of Directors (the “Board”) of Spero Therapeutics, Inc. (the “Company”) appointed Esther Rajavelu as the Company’s Chief Financial Officer and Chief Business Officer.
View on SEC.gov

Spero Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-23-267758
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.